Topic: drug reimbursement
Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.
Back in June, England’s cost watchdog refused to recommend Roche’s Perjeta for postsurgery breast cancer patients. And it’s sticking by that decision.
A couple of drugmakers are celebrating this week after favorable decisions from England’s cost watchdog.
England’s cost watchdogs aren’t going to pay for Roche's Ocrevus, the only approved PPMS therapy—that is, until it gets cheaper.
NICE is now endorsing Ocrevus for NHS coverage in relapsing-remitting MS and will deliver a decision on the primary progressive form soon.
England’s cost watchdogs are blocking reimbursement of Roche's Perjeta for some postsurgery patients with early breast cancer.
Zilretta has several things going for it. It's not an opioid painkiller and it lasts longer than rival shots. So why isn't its launch speeding ahead?
CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's requested add-on payment.
Crowding in the MS field hasn’t stopped Roche's Ocrevus from making a splash. But that competition has made it tough to snag reimbursement in England.
Merck just pulled off a coverage feat that some of its immuno-oncology rivals haven’t so far.